Kyowa Kirin Receives Positive CHMP Opinion for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH), a Rare Metabolic Bone Disorder

Self-administration of CRYSVITA could offer additional options for healthcare professionals to meet the needs of XLH patients and their carers, ensuring continuity of therapy during and beyond the COVID-19 pandemic TOKYO--(BUSINESS WIRE)--Kyowa Kirin ...

Full "IntellAsia: Resources" article